Syndax Pharmaceuticals Inc — Director's Dealing 2021

Dec 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-12-16

Reporting Person: Metzger Michael A (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-16	Common Stock	M	22715.00	$6.38	Acquired	40374.00	Direct
2021-12-16	Common Stock	S	22715.00	$19.0799	Disposed	17659.00	Direct
2021-12-17	Common Stock	M	1676.00	$6.38	Acquired	19335.00	Direct
2021-12-17	Common Stock	S	1676.00	$19.0198	Disposed	17659.00	Direct
2021-12-20	Common Stock	M	16000.00	$6.38	Acquired	33659.00	Direct
2021-12-20	Common Stock	S	16000.00	$20.288	Disposed	17659.00	Direct
2021-12-20	Common Stock	M	45000.00	$8.77	Acquired	62659.00	Direct
2021-12-20	Common Stock	S	45000.00	$20.288	Disposed	17659.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-16	Stock Options (Right to buy)	$6.38	M	22715.00	Disposed	2029-02-06	Common Stock (22715.00)	Direct
2021-12-17	Stock Options (Right to buy)	$6.38	M	1676.00	Disposed	2029-02-06	Common Stock (1676.00)	Direct
2021-12-20	Stock Options (Right to buy)	$8.77	M	45000.00	Disposed	2027-02-06	Common Stock (45000.00)	Direct
2021-12-20	Stock Options (Right to buy)	$6.38	M	16000.00	Disposed	2029-02-06	Common Stock (16000.00)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 596,031 options to purchase shares of common stock that are vested and immediately exercisable and a total of 335,209 options to purchase shares of common stock that have not yet vested.

F2: The sale prices ranged from $19.00 to $19.30.

F3: The sale prices ranged from $19.00 to $19.06.

F4: The sale prices ranged from $19.17 to $21.01

F5: This option is fully vested.